KCM
BEAM icon

Kynam Capital Management’s Beam Therapeutics BEAM Stock Holding History

Kynam Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-937,000
Closed -$26M – 40
2025
Q4 		$26M Buy
+937,000
New +$23.9M 1.66% 18

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Kynam Capital Management's BEAM Position: Q1 2026 in Review

Kynam Capital Management increased its Beam Therapeutics (BEAM) stake by 51% in Q1 2026, buying an estimated $34.5M and bringing the position to 3,682,185 shares worth $87.7M. The position accounts for 5.41% of the portfolio, ranked #6.

Kynam Capital Management first reported a position in BEAM in Q3 2024 and has held it in 7 quarters since. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Kynam Capital Management held 3,682,185 shares of Beam Therapeutics worth $87.7M as of Q1 2026.
  • Kynam Capital Management bought 1,241,971 Beam Therapeutics shares in Q1 2026, an estimated $34.5M.
  • Beam Therapeutics made up 5.41% of Kynam Capital Management's portfolio in Q1 2026, its #6 holding.
  • Kynam Capital Management first reported a position in Beam Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.